Holen Sie sich die Stockscreener-App
6.56
4.51%
-0.31
Handel nachbörslich:
6.97
0.41
+6.25%
Schlusskurs vom Vortag:
$6.87
Offen:
$6.75
24-Stunden-Volumen:
1.22M
Relative Volume:
0.72
Marktkapitalisierung:
$272.70M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-3.4709
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+4.13%
1M Leistung:
+8.43%
6M Leistung:
+429.03%
1J Leistung:
+250.80%
1-Tages-Spanne:
$6.51
$7.15
1-Wochen-Bereich:
$6.10
$7.15
52-Wochen-Spanne:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.56 | 434.45M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Eingeleitet | Leerink Partners | Outperform |
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Best data tools to analyze Immuneering Corporation stockAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Is Immuneering Corporation stock undervalued vs historical averagesTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
Will Immuneering Corporation stock outperform value stocksPortfolio Growth Summary & Momentum Based Trading Signals - newser.com
Is Immuneering Corporation stock positioned well for digital economyGap Up & Entry Point Strategy Guides - newser.com
What indicators show strength in Immuneering CorporationWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Can momentum traders help lift Immuneering CorporationPortfolio Value Summary & Stepwise Swing Trade Plans - newser.com
Can Immuneering Corporation stock sustain institutional interestBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
Immuneering (NASDAQ:IMRX) Upgraded at Leerink Partnrs - MarketBeat
Trend analysis for Immuneering Corporation this week2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Leerink Partners Initiates Coverage on Immuneering (NASDAQ:IMRX) - MarketBeat
Top chart patterns to watch in Immuneering CorporationMarket Trend Review & Community Shared Stock Ideas - newser.com
What’s the recovery path for long term holders of Immuneering CorporationWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Published on: 2025-10-31 05:51:06 - newser.com
How Immuneering Corporation stock valuations compare to rivals2025 Big Picture & Fast Gaining Stock Reports - newser.com
How to build a dashboard for Immuneering Corporation stock2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Will Immuneering Corporation stock benefit from automationJuly 2025 Volume & Daily Entry Point Alerts - newser.com
Has Immuneering Corporation formed a bullish divergence2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Can Immuneering Corporation rally from current levelsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Can machine learning forecast Immuneering Corporation recoveryJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
How strong is Immuneering Corporation stock balance sheetJuly 2025 Setups & Expert Verified Stock Movement Alerts - newser.com
Is Immuneering Corporation stock attractive for growth ETFsJuly 2025 Final Week & Consistent Growth Equity Picks - fcp.pa.gov.br
What institutional flow reveals about Immuneering CorporationForecast Cut & Capital Efficient Trade Techniques - newser.com
Forecasting Immuneering Corporation price range with options dataMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Can Immuneering Corporation stock withstand economic slowdownJuly 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Regression analysis insights on Immuneering Corporation performance2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):